vs

Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and SurgePays, Inc. (SURG). Click either name above to swap in a different company.

SurgePays, Inc. is the larger business by last-quarter revenue ($16.2M vs $12.5M, roughly 1.3× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -85.6%, a 86.9% gap on every dollar of revenue. On growth, SurgePays, Inc. posted the faster year-over-year revenue change (68.7% vs -0.7%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs -28.2%).

SurgePays, Inc. is a U.S.-headquartered fintech and telecommunications company focused on serving underbanked and low-income communities across the country. It offers prepaid wireless plans, reloadable debit cards, digital banking solutions, and daily consumer products through a nationwide network of independent local retail partners such as convenience stores.

SLSN vs SURG — Head-to-Head

Bigger by revenue
SURG
SURG
1.3× larger
SURG
$16.2M
$12.5M
SLSN
Growing faster (revenue YoY)
SURG
SURG
+69.3% gap
SURG
68.7%
-0.7%
SLSN
Higher net margin
SLSN
SLSN
86.9% more per $
SLSN
1.3%
-85.6%
SURG
Faster 2-yr revenue CAGR
SLSN
SLSN
Annualised
SLSN
12.5%
-28.2%
SURG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SLSN
SLSN
SURG
SURG
Revenue
$12.5M
$16.2M
Net Profit
$163.0K
$-13.9M
Gross Margin
27.5%
-14.8%
Operating Margin
1.5%
-79.1%
Net Margin
1.3%
-85.6%
Revenue YoY
-0.7%
68.7%
Net Profit YoY
129.2%
30.0%
EPS (diluted)
$0.00
$-0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLSN
SLSN
SURG
SURG
Q4 25
$12.5M
$16.2M
Q3 25
$14.6M
$18.7M
Q2 25
$20.4M
$11.5M
Q1 25
$14.6M
$10.6M
Q4 24
$12.6M
$9.6M
Q3 24
$16.9M
$4.8M
Q2 24
$13.0M
$15.1M
Q1 24
$9.9M
$31.4M
Net Profit
SLSN
SLSN
SURG
SURG
Q4 25
$163.0K
$-13.9M
Q3 25
$-1.1M
$-7.5M
Q2 25
$2.7M
$-7.1M
Q1 25
$80.0K
$-7.6M
Q4 24
$-559.0K
$-19.8M
Q3 24
$3.0M
$-14.3M
Q2 24
$856.0K
$-12.9M
Q1 24
$893.0K
$1.2M
Gross Margin
SLSN
SLSN
SURG
SURG
Q4 25
27.5%
-14.8%
Q3 25
23.1%
-13.9%
Q2 25
28.9%
-23.0%
Q1 25
23.1%
-27.8%
Q4 24
22.0%
-117.0%
Q3 24
36.2%
-164.2%
Q2 24
28.7%
-22.8%
Q1 24
36.3%
26.0%
Operating Margin
SLSN
SLSN
SURG
SURG
Q4 25
1.5%
-79.1%
Q3 25
-5.4%
-37.2%
Q2 25
9.4%
-59.1%
Q1 25
1.8%
-71.7%
Q4 24
-1.8%
-209.0%
Q3 24
19.0%
-299.4%
Q2 24
8.0%
-72.1%
Q1 24
11.3%
5.6%
Net Margin
SLSN
SLSN
SURG
SURG
Q4 25
1.3%
-85.6%
Q3 25
-7.7%
-40.1%
Q2 25
13.1%
-61.5%
Q1 25
0.5%
-72.2%
Q4 24
-4.4%
-206.5%
Q3 24
18.1%
-299.3%
Q2 24
6.6%
-85.3%
Q1 24
9.0%
3.9%
EPS (diluted)
SLSN
SLSN
SURG
SURG
Q4 25
$0.00
$-0.68
Q3 25
$-0.02
$-0.38
Q2 25
$0.04
$-0.36
Q1 25
$0.00
$-0.38
Q4 24
$0.00
$-1.07
Q3 24
$0.04
$-0.73
Q2 24
$0.01
$-0.66
Q1 24
$0.02
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLSN
SLSN
SURG
SURG
Cash + ST InvestmentsLiquidity on hand
$1.3M
$1.7M
Total DebtLower is stronger
$13.3M
Stockholders' EquityBook value
$17.6M
$-15.3M
Total Assets
$50.1M
$8.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SLSN
SLSN
SURG
SURG
Q4 25
$1.3M
$1.7M
Q3 25
$429.0K
$2.5M
Q2 25
$4.1M
$4.4M
Q1 25
$1.8M
$5.4M
Q4 24
$1.4M
$11.8M
Q3 24
$2.9M
$23.7M
Q2 24
$2.4M
Q1 24
$2.0M
Total Debt
SLSN
SLSN
SURG
SURG
Q4 25
$13.3M
Q3 25
$12.0M
Q2 25
$9.6M
Q1 25
$3.6M
Q4 24
$4.0M
Q3 24
$4.4M
Q2 24
$4.8M
Q1 24
$5.2M
Stockholders' Equity
SLSN
SLSN
SURG
SURG
Q4 25
$17.6M
$-15.3M
Q3 25
$17.2M
$-6.4M
Q2 25
$18.2M
$116.1K
Q1 25
$15.2M
$7.8M
Q4 24
$14.9M
$15.3M
Q3 24
$15.2M
$33.2M
Q2 24
$11.9M
$46.2M
Q1 24
$5.0M
$56.0M
Total Assets
SLSN
SLSN
SURG
SURG
Q4 25
$50.1M
$8.5M
Q3 25
$54.0M
$14.5M
Q2 25
$60.0M
$15.2M
Q1 25
$57.0M
$15.7M
Q4 24
$50.0M
$24.0M
Q3 24
$48.0M
$41.5M
Q2 24
$40.8M
$56.4M
Q1 24
$38.5M
$69.6M
Debt / Equity
SLSN
SLSN
SURG
SURG
Q4 25
Q3 25
Q2 25
82.67×
Q1 25
0.46×
Q4 24
0.26×
Q3 24
0.13×
Q2 24
0.10×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SLSN
SLSN
SURG
SURG
Operating Cash FlowLast quarter
$1.8M
$-3.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
11.16×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SLSN
SLSN
SURG
SURG
Q4 25
$1.8M
$-3.6M
Q3 25
$-2.5M
$-4.6M
Q2 25
$-654.0K
$-6.1M
Q1 25
$-7.2M
$-7.0M
Q4 24
$2.2M
$-7.9M
Q3 24
$4.2M
$-13.3M
Q2 24
$-565.0K
$-4.1M
Q1 24
$-3.9M
$4.0M
Free Cash Flow
SLSN
SLSN
SURG
SURG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-404.0K
Q3 24
$2.8M
Q2 24
$-1.0M
Q1 24
$-3.9M
FCF Margin
SLSN
SLSN
SURG
SURG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-3.2%
Q3 24
16.6%
Q2 24
-8.0%
Q1 24
-39.9%
Capex Intensity
SLSN
SLSN
SURG
SURG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
20.6%
Q3 24
8.3%
Q2 24
3.7%
Q1 24
0.9%
Cash Conversion
SLSN
SLSN
SURG
SURG
Q4 25
11.16×
Q3 25
Q2 25
-0.25×
Q1 25
-90.26×
Q4 24
Q3 24
1.38×
Q2 24
-0.66×
Q1 24
-4.32×
3.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons